Exact Sciences reports Q1 loss that matches analysts’ expectations
Exact Sciences Corp. on Wednesday reported a first-quarter loss that matched analysts’ expectations and revenue that beat expectations. The Madison-based maker of the Cologuard colon cancer test reported a first-quarter loss of $110.2 million, or $0.60 per …